Management expects only inconsequential U.S. NEXUS revenue during 2026, though it may perform some ad hoc cases before the planned commercial rollout. As of June 30, Artivion had $77.3 million in cash and $363 million in debt, net of $6.6 million of unamortized loan origination costs. Berry noted that a $25 million AMDS PMA milestone payment was made in July and was not included in the quarter-end leverage calculation. Looking to 2027, Berry said Artivion expects NEXUS to begin making meaningful revenue contributions following its planned January launch. Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.